Clinical Trial Search

Primary: Difference in Ashworth Spasticity Scale Score Between Baseline and 12 Weeks — -1.55; -1.00 units on a scale

Primary: Impact of Spasticity, Measured by the Multiple Sclerosis Spasticity Scale-88 — -16.11; -15.83 units on a scale

Primary: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) — -0.23; -0.26 units on a scale — p=0.7152

Primary: Number of Participants With Adverse Events, Change in Vital Signs, Clinical Laboratory Test Results, 12-lead ECGs, USP Questionnaire, and C-SSRS Results — 276 Participants

Primary: Change From Baseline in Total Numeric-transformed Modified Ashworth Scale Score of the Most Affected Limb (TNmAS-MAL) — -1.7; -2.0; -1.4 units on a scale

Primary: Change From Baseline in Mean Spasticity 0-10 Numerical Rating Scale (NRS) Score During the Last 14 Day of Treatment (End of Treatment) — -1.22; -0.91 units on a scale…

Primary: MS Walking Scale-12 (MSWS-12) — 72.6; 82.2 units on a scale — p=0.84

Primary: Assessment of Change From Baseline in the Mean Spasticity 0-10 Numerical Rating Scale Score. — -1.18; -0.63 units on a scale — p=0.048

Primary: Kinematics — 15.5; 10 degrees

Primary: Number of Subjects With Adverse Events — 129; 150; 44 Count of participants

Primary: Least Square Mean Difference (Placebo Versus Each SPARC1103 Dose) in Change From Baseline in Modified Ashworth Score — 0.33; 0.03 score on a scale

Primary: The Change in Mean Spasticity Numerical Rating Scale (NRS) Score From Baseline to End of Treatment (Phase B). — 3.68; 4.56 Points on scale — p=0.0002

Primary: Number of Participants Classified as Upper Limb Responders on the 9 Hole Peg Test (9HPT) — 4; 3; 58; 59 Participants

Primary: Peak Activity Index — 0.6; 0.3 change in strides per minute — p=0.586

Primary: Proportion of Participants Achieving a Mean Improvement of ≥ 8 Points From Baseline on the Multiple Sclerosis Walking Scale (MSWS-12) Over 24 Weeks — 0.336; 0.432…

Primary: Expanded Disability Status Score — 6.8 score on a scale

Primary: Participant Muscle Stiffness Measure — 350.83; 240.07 Newton-metres

Primary: Change From Baseline to the End of Treatment in Paced Auditory Serial Addition Test (PASAT) Total Score. — 6.8; 6.8 units on a scale

Primary: Walking Endurance — 42; 25 meters

Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11

Primary: The Brief Repeatable Battery of Rao — 42.09; 35.5 Correct words — p=0.028

Primary: Number of Subjects Who Experience Treatment Failure. — 8; 17 Participants — p=0.013

Primary: Distance Walked on a Treadmill With tDCS — 375; 285 m

Primary: Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6 — -0.99; -0.43 units on a scale — p=0.0140

Primary: Fatigue — 21; 24 % decline

Primary: Median Percent Change From Baseline in Average Walking Speed on Timed 25-Foot Walk Test — 1.2; 7.5; 9.7; 6.9 percent change

Primary: Physician Assessment of Spasticity

Primary: Area Under the Curve (AUC) for the Change From Baseline in Modified Ashworth Scale (MAS) Wrist Score to the End of the DB Phase (Week 12) in the High-dose Groups…

Primary: Change From Baseline in the Mean Daily Number of Incontinence Episodes at the End of Treatment — -1.08; -0.99 number of daily episodes — p=0.569

Primary: Study Feasibility: Number of Participants Recruited — 24 Participants